Lagevrio (molnupiravir) added $3.2 billion to Merck's top line of $15.9 billion, but even without the drug sales would have risen 19% thanks to a strong performance from cancer immunotherapy ...

Maybe you've been in a room recently with someone who's coughing, but they say "I promise it's not COVID." While it's important to still be cautious about COVID-19, there are other viral ...

Sales of Lagevrio (molnupiravir) declined 37% to $121 million in the quarter. The segment generated revenues of $1.40 billion, up 9% year over year (13% excluding Fx impact). This growth was ...

Molnupiravir (Lagevrio): An oral antiviral authorized for emergency use in treating mild to moderate COVID-19 in adults at high risk of severe disease when other treatment options are inaccessible ...

Merck MRK reported fourth-quarter 2024 adjusted earnings per share (EPS) of $1.72, which beat the Zacks Consensus Estimate of $1.69. In the year-ago period, management reported adjusted EPS of 3 cents ...

There's still no cure for the common cold. Cold medicines seek to relieve symptoms rather than cure the illness or make it go away faster. Over-the-counter (OTC) medicines and self-care may help ...

Molnupiravir (Lagevrio, Lizuvira) is a potent ribonucleoside analog acts as an antiviral agent. It is formulated as hard capsules for oral route of administration. Lagevrio is indicated for treatment ...

Sum of quarterly amounts may not equal year-to-date amounts due to rounding. (1) Only select products are shown. (2) Alliance Revenue represents Merck’s share of profits, which are product sales ...